HZO (Herpes Zoster Ophthalmicus)/shingles near eye; Herpes zoster/ shingles; This spontaneous case was reported by a consumer and describes the occurrence of OPHTHALMIC HERPES ZOSTER (HZO (Herpes Zoster Ophthalmicus)/shingles near eye) and HERPES ZOSTER (Herpes zoster/ shingles) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In April 2021, the patient experienced OPHTHALMIC HERPES ZOSTER (HZO (Herpes Zoster Ophthalmicus)/shingles near eye) (seriousness criterion medically significant) and HERPES ZOSTER (Herpes zoster/ shingles) (seriousness criterion medically significant). The patient was treated with DIFLUPREDNATE (DUREZOL) at an unspecified dose and frequency; PREDNISONE at an unspecified dose and frequency; VALACYCLOVIR [VALACICLOVIR] (oral) at a dose of 1 gram once a day and FLUOROMETHOLONE (FML) at an unspecified dose and frequency. At the time of the report, OPHTHALMIC HERPES ZOSTER (HZO (Herpes Zoster Ophthalmicus)/shingles near eye) and HERPES ZOSTER (Herpes zoster/ shingles) had not resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant information was not provided.  It was reported that after the first dose of the vaccine few days before 25-Apr-2021, patient experienced severe pounding headaches. She had rash on her forehead and severe pain. Patient noticed rash on her scalp .  It was reported that patient was taking Durezol before switching over to FML.  Company comment: This case concerns a 54-year-old female patient with no relevant medical history reported, who experienced the serious unexpected events of Ophthalmic herpes zoster and herpes zoster. The events occurred the on an unknown date on the next month after the first dose of mRNA-1273. She was not hospitalized over night and discharged. The patient stated she will have to be on treatment for the rest of her life , as the events are ongoing, because of Ophthalmic herpes zoster. The rechallenge was not applicable since only information about the first dose was disclosed. The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to MOD-2021-403704, MOD-2021-404966 (Patient Link).; Sender's Comments: This case concerns a 54-year-old female patient with no relevant medical history reported, who experienced the serious unexpected events of Ophthalmic herpes zoster and herpes zoster. The events occurred the on an unknown date on the next month after the first dose of mRNA-1273. She was not hospitalized over night and discharged. The patient stated she will have to be on treatment for the rest of her life , as the events are ongoing, because of Ophthalmic herpes zoster. The rechallenge was not applicable since only information about the first dose was disclosed. The benefit-risk relationship of mRNA-1273 is not affected by this report.